• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sentinel Oncology Limited - Product Pipeline Review - 2012 Product Image

Sentinel Oncology Limited - Product Pipeline Review - 2012

  • Published: July 2012
  • 24 pages
  • Global Markets Direct

Sentinel Oncology Limited – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Sentinel Oncology Limited - Product Pipeline Review - 2012” provides data on the Sentinel Oncology Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sentinel Oncology Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Sentinel Oncology Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Sentinel Oncology Limited - Brief Sentinel Oncology Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sentinel Oncology Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline READ MORE >

2
List of Tables 3
List of Figures 3
Sentinel Oncology Limited Snapshot 4
Sentinel Oncology Limited Overview 4
Key Information 4
Key Facts 4
Sentinel Oncology Limited – Research and Development Overview 5
Key Therapeutic Areas 5
Sentinel Oncology Limited – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
Sentinel Oncology Limited – Pipeline Products Glance 9
Sentinel Oncology Limited – Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Sentinel Oncology Limited – Drug Profiles 11
Checkpoint Kinase 1 Inhibitor Program 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
FMS-like tyrosine kinase 3 (FLT3) Inhibitor Program 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
P70S6k Inhibitor 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
TS-Chk1 Inhibitor Program 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Sentinel Oncology Limited – Pipeline Analysis 15
Sentinel Oncology Limited – Pipeline Products by Therapeutic Class 15
Sentinel Oncology Limited – Pipeline Products By Target 16
Sentinel Oncology Limited – Pipeline Products by Route of Administration 17
Sentinel Oncology Limited – Pipeline Products By Mechanism of Action 18
Sentinel Oncology Limited – Locations And Subsidiaries 19
Head Office 19
Financial Deals Landscape 20
Sentinel Oncology Limited, Deals Summary 20
Sentinel Oncology Limited, Pharmaceuticals & Healthcare, Deal Details 21
Venture Financing 21
Sentinel Oncology Secures $0.18 Million In Venture Financing 21
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables
Sentinel Oncology Limited, Key Information 4
Sentinel Oncology Limited, Key Facts 4
Sentinel Oncology Limited – Pipeline by Indication, 2012 6
Sentinel Oncology Limited – Pipeline by Stage of Development, 2012 7
Sentinel Oncology Limited – Monotherapy Products in Pipeline, 2012 8
Sentinel Oncology Limited – Pre-Clinical, 2012 9
Sentinel Oncology Limited – Discovery, 2012 10
Sentinel Oncology Limited – Pipeline By Therapeutic Class, 2012 15
Sentinel Oncology Limited - Pipeline By Target, 2012 16
Sentinel Oncology Limited – Pipeline By Route of Administration, 2012 17
Sentinel Oncology Limited – Pipeline Products By Mechanism of Action, 2012 18
Sentinel Oncology Limited, Deals Summary 20
Sentinel Oncology Secures $0.18 Million In Venture Financing 21

List of Figures
Sentinel Oncology Limited – Pipeline by Indication, 2012 6
Sentinel Oncology Limited – Pipeline by Stage of Development, 2012 7
Sentinel Oncology Limited – Monotherapy Products in Pipeline, 2012 8
Sentinel Oncology Limited – Pipeline By Therapeutic Class, 2012 15
Sentinel Oncology Limited - Pipeline By Target, 2012 16
Sentinel Oncology Limited - Pipeline Products By Mechanism of Action, 2012 18

Note: Product cover images may vary from those shown

RELATED PRODUCTS